Uchihashi Y, Kuribara H, Isa Y, Morita T, Sato T
Department of Anesthesiology, National Defense Medical College, Tokorozawa, Japan.
Psychopharmacology (Berl). 1994 Sep;116(1):40-4. doi: 10.1007/BF02244869.
The involvement of dopaminergic mechanisms in ketamine-induced disruption of one trial step-through passive avoidance performance was assessed through the coadministration with the dopamine D1 antagonist SCH 23390, the dopamine D2 antagonist YM-091512 and the dopamine autoreceptor agonist at low doses, apomorphine, in mice. Pretraining (10 min before) administration of ketamine (0; saline, 2.5, 5 and 10 mg/kg SC) dose-dependently reduced the latency in the retention trial conducted 24 h after the training. However, ketamine did not affect the retention latency when administered immediately after the training or prior to retention. YM-09151-2 (0.01 and 0.03 mg/kg SC) and apomorphine (0.01 and 0.03 mg/kg SC), but not SCH 23390 (0.01 and 0.03 mg/kg SC), ameliorated the impaired reduction by ketamine (10 mg/kg) in a dose-dependent manner. These results suggest that ketamine obstructs the acquisition of the passive avoidance task, and that this effect is induced by stimulation of dopamine D2 receptors through dopamine release from the presynaptic terminals.
通过与多巴胺D1拮抗剂SCH 23390、多巴胺D2拮抗剂YM-091512以及低剂量多巴胺自身受体激动剂阿扑吗啡共同给药,评估多巴胺能机制在氯胺酮诱导的单次试验穿梭式被动回避行为破坏中的作用。氯胺酮(0;生理盐水、2.5、5和10 mg/kg皮下注射)在预训练(训练前10分钟)给药时,剂量依赖性地缩短了训练后24小时进行的记忆试验中的潜伏期。然而,氯胺酮在训练后立即给药或在记忆试验前给药时,并不影响记忆潜伏期。YM-09151-2(0.01和0.03 mg/kg皮下注射)和阿扑吗啡(0.01和0.03 mg/kg皮下注射),而不是SCH 23390(0.01和0.03 mg/kg皮下注射),以剂量依赖性方式改善了氯胺酮(10 mg/kg)导致的受损减少。这些结果表明,氯胺酮阻碍了被动回避任务的获得,并且这种作用是通过突触前终末释放多巴胺刺激多巴胺D2受体诱导的。